Europe Reveals a Non-Surgical, Cataract Removal Option.

Robert_Mason“26,000 individuals develop serious complications as a result of cataract surgery annually in the US alone.Thus, risk and cost factors drive the investigation of pharmaceutical approaches to the maintenance of lens transparency. Opacification of the posterior lens capsule occurs in 30-50% of patients within 2 years of cataract removal and require secondary laser treatment; further 0.8% experience retinal detachments, approximately 1% are re-hospitalized for corneal problems, and about 0.1% develop endophthalmitis.

The significant complication rate of cataract surgery, should be sufficient reason to increase cataract research. Additionally the artificial lens just does not have the same overall optical qualities of a natural lens.

Even if the development of cataract can be delayed by 10-years, the overall benefits would be highly significant..:” Dr. Robert Mason PhD – “Guide to Anti Aging Drugs”

In clinical trials patients instilled 2 drops of a proprietary form of N-acetyl-carnosine eye drop into each eye 3 to 4 times a day, for a period of 6 months. The results showed a pronounced effect on cataracts; the effective rate was 100%, setting an unprecedented benchmark for the treatment and reversal of cataracts and other eye disorders..” Clinical Publications

Over the last 10 years this, non-invasive, anti-oxidant, eye drop, patented by “Innovative Vision Products” has generated thousands of reports of safe and effective Cataract Reversal. Can-C™ Testimonials!

news06Innovative Vision Products (IVP)is a US based corporation founded by Dr. Mark Babizhayev, operating in Russia in co-operation with the “Helmholtz Research Institute of Eye Disease” Moscow.

The Product: N-acetylcarnosine (Can-C™), is manufactured in a cGMP facility by a UK based licensed manufacturer and we see the demand for this product snowballing as consumers around the globe become aware of a viable non-surgical option to cataract surgery.”

In addition to the very impressive statistical and clinical success rates for patients within 3-12 months of treatment, it is also interesting to note that NAC eye-drops are patented for use in open-angle glaucoma, but as yet, the research for that disorder remains unpublished. [Ed.- We are keen to report on NAC’s benefit for glaucoma as soon as it becomes available, especially as this is an eye-disorder that is extremely difficult to treat.]

Mark Babizhayev MA, PhD

The statistics in the human trials show that Can-C™ Eye Drops applied for 6-months, (twice daily into the eye), in patients suffering from senile cataract, had the following results:

  • 90% had an improvement in visual acuity.
  • 88.9% had an improvement of glare sensitivity.
  • 41.5% had an improvement of the transmissivity of the lens.

“Hello,I used Can-C™ eye drops for 4-months with amazing results. My vision in my left eye improved from 20/40 to 20/25 and upon renewal of my driving license, the eye glass restriction was eliminated!”Dr. Richard Lippman, Hawaii

“Dr. Babizhayev, I want to thank you for the ‘great’ and ‘unbelieveable’ and ‘marvelvelous’ eye drops that you have developed. I use vitamin supplemets for my eyes but without your N-acetylcarnosine ‘eye drops’, I know that I would be totally ‘blind’ today from cataracts. I want you to know that I will continue to use these eye drops indefinitely for maintaining the improved health of my eyes. Thank you! Lawrence H. – Tucson AZ

More Testimonials

Important Reading..

The prime ingredient in Can-c™ is a proprietary form of N-acetylcarnosine. A highly specific intraocular released form of carnosine, patented by Innovative Vision Products, which acts as both a stabilizer and carrier for the di-peptide L-carnosine, safely delivering it into the aqueous humour of the eye, (the fluid area surrounding the lens). It is here, that this bio-identical antioxidant becomes most active in its anti-cataract activity.

What about other eye conditions…?

Although the information is not yet published, this unique “IVP” N-acetylcarnosine (Can-C™) formula with its synergistic lubricants, and bioavailable antioxidant properties, is showing impressive beneficial results for the following eye-disorders.• Intraocular pressure associated with Glaucoma.


  • Contact lens disorders.
  • Presbyopia
  • Corneal disorders.
  • Chronic eyestrain.
  • Computer vision syndrome.
  • Ocular inflammation.
  • Blurred vision.
  • Dry eye syndrome.
  • Retinal disease
  • Vitreous opacities and lesions.

Note: Not only do the lubricants in the Can-C N-acetylcarnosine eye-drop help to make wearing contact lenses more comfortable, but n-acetylcarnosine is also believed to reduce the build up of lactic acid in the eye, thus enabling the lens to be left safely in the eye for longer.

Manufactured to cGMP pharmaceutical standards, Can-C™ has a wealth of anti-oxidant properties which can improve the overall function of the aging eye.

Can-C Two (5ml) vials per box. Apply 4 drops daily to each affected eye

  • 1 month supply for both eyes = 2 boxes
  • 2 month supply for both eyes = 4 boxes
  • 4 month supply for both eyes = 8 boxes
  • 6 month supply for both eyes = 12 boxes

Ordering Information-click here

$39.00 or $37.05 / month

Initial results in only 3 months time! Optimal Results within 6 – 12 months!

Initial results in only 3 months time! Optimal Results within 6 – 12 months!

Product Questions? 1-800.861.4936

Human trials

Carnosine eye-drops were used in a clinical trial to treat 96 patients aged 60 and above. All the patients had senile cataract in various degrees of maturity. The duration of the disease in these patients ranged between 2 and 21 years. Firstly, the researchers stopped the patient’s use of all other anti-cataract drugs. Then the patients instilled 1 or 2 drops into each eye 3 or 4 times a day, for a period of 3 to 6 months.

The level of eyesight improvement and the change of lens transparency was considered as an evaluation index. The results showed that there was a pronounced effect on primary senile cataract, the effective rate was 100% (i.e. all patients experienced an improvement. For the more mature senile cataract (i.e. those who had had the cataract the longest time, in some cases more than 20-years) the effective rate was still an extremely impressive 80%. These are remarkable results considering that the best that could normally be expected would be a slight improvement, a halt to the progression and under normal (i.e. non-treated) circumstances a continual worsening of the disease. Importantly, it was also noted that there were no side effects noted in any of the cases.Clinical Publications

eye exam

Another Russian study was designed to document and quantify the changes in lens clarity over a 6 to 24 month period for 49 volunteers. Their average age was 65 and all suffered from senile cataract of a minimal to advanced opacification.

The patients received either a 1% solution of NAC eye-drops or a placebo, as 2-drops twice a day into each eye. The patients were then evaluated at 2 and 6-month periods. The tests consisted of ophthalmoscopy (glare test), stereocinematagraphic (slit-image) and retro-illumination (photography). A computerized digital analysis then displayed the light scattering and absorbing effects of the centers of each lens.

At 6-months, 88.9% of all eyes treated with NAC had an improvement of glare sensitivity (lowest individual score was a 27% improvement, right the way up to a 100% improvement. 41.5% of all eyes treated with NAC had a significant improvement of the transmissivity of the lens, but perhaps most importantly 90% of the eyes treated with NAC showed an improvement in visual acuity. Meanwhile, in the placebo group there was little change in eye quality at 6-months and a gradual deterioration at 12 to 24 months. Importantly, this study also showed that at 24-months the NAC treated group, (who already had significant improvement to the quality of their eyesight), sustained these results with continued use of the NAC eye-drops. Once again, no significant side effects were noted in any cases throughout the 2-year period.

Another interesting study evaluated patients between the ages of 48 and 60, who had various degrees of eyesight impairment, but who did NOT have the symptoms of cataract. After a course of treatment ranging from 2 to 6 months the conclusion was, that the eye-drops alleviated eye-tiredness and continued to improve eyesight (i.e. there was more clear vision). The subjects reported that the treatment “brightened” and “relaxed” their eyes. This is an important indicator that the eye-drops have a value both for preventative purposes, as well as medical applications.

eyeanatomyAt this time clear evidence has emerged that NAC eye-drops are a safe, effective treatment and potential preventative against cataract however Dr. Mark Babizhayev also makes it quite clear that “ordinary” L-Carnosine will not be of much use in the treatment of senile-cataract. This is because there are many synthesized “carnosines” and their biological and medicinal activity strongly varies and depends on the mode of their obtention. For example, if carnosine is extracted from meat muscle substances, the biological and anti-oxidant activity is very low. This is presumably due to the contamination of the “pure” carnosine substance by heavy metal salts and proteins and other related impurities. It is very difficult to purify carnosine chromatographically, as the compound chelates divalent metal ions very heavily and the biological and anti-oxidant activities can not be regenerated during the purification procedures. Ed.- See Dr. Babizhayev Interview

How N-acetylcarnosine (Can-C™) actually reverses cataracts – Click Here

So in conclusion, NAC eye-drops appear to act as a universal anti-oxidant, both in the lipid phase of the cellular lens membranes, and in the aqueous environment. NAC eye-drops reduce and protect the crystalline lens from oxidative stress-induced, cross-linking damage. There were many forms of carnosine, which were abandoned, in the Russian studies because of their lack of anti-cataract and anti-oxidant ability in the human eye, however, Innovative Vision Products (IVP), in conjunction with their Japanese partner and manufacturer, have developed a synthesized pure NAC which has biological activity and has been well controlled and proven in human lens studies. This is the formula that has been used in the clinical trials under th etrademark name Can-C™.

IVP holds the proprietary knowledge to the correct and efficient production of a specific purity of NAC. If the label doesn’t state it is Approvedby Innovative Vision Products (IVP), then the source of the raw material is NOT the one that the clinical trials were conducted with. “Unknown” sources of carnosine eye-drops should be avoided, as the material could be ineffective, and possibly even dangerous to the human eye.

“Cataract is a widespread age-related affliction and NAC eye-drops appear to be a highly efficacious and safe treatment for cataract. As such, I suspect that this supplement is going to become one of the most important new discoveries, and will have a major impact on the way that cataract is controlled.” – Mark Babizhayev MA, PhD

In our study the clinical effects of a topical solution of N-acetylcarnosine eye drops (Can-C™) on lens opacities were examined in patients with cataracts and in canines with age-related cataracts.These data showed that N-acetylcarnosine (Can-C™) is effective in the management of age-related cataract reversal and prevention both in human and in canine eyes.” Continue Reading..

PMID: 15139774 [PubMed – indexed for MEDLINE]

Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. PMID: 15139774 [PubMed – indexed for MEDLINE] Innovative Vision Products Inc., County of New Castle, Delaware, USA.


  1. Boldyrev AA, Dupin AM, Bunin Aya, Babizhayev MA, Severin SE “The antioxidative properties of carnosine, a natural histidine containing di-peptide.” Biochem. Inrern., 1987, 15/6, 1105-1113.
  2. Babizhayev MA et al “N-Acetylcarnosine, a natural histidine-containing di-peptide, as a potent ophthalmic drug in treatment of human cataracts.” Peptides (USA) 2001, 22(6): 979-994.
  3. Babizhayev MA, Yermakova VN, Deyev Al, Seguin M-C “Imidazole-containing peptiomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans.” J. Anti-Aging Medicine 2000, 2, 43-62.
  4. Babizhayev MA, Yermakova VN, Semiletov yu A, Deyev Al “The natural histidine-containing di-peptide N-acetylcarnosine as an antioxidant for ophthalmic use.” Biochemistry (Moscow), 2000, 65, 588-598.
  5. Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva RP, Rozhkova EA, Zheltukhina GA “N-Acetycarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant.” Clin. Chim. Acta., 1996, 254, 1-21.
  6. Babizhayev MA, Bozzo Costa E “Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta.” A61K gruppo 37/00 cap 20122 MI 15.10.1993. Italian patent.
  7. Babizhayev MA, Bozzo Costa E “Pharmaceutical compositions containing N-Acetylcarnosine for the treatment of cataract.” European Patent PCT/EP 94/03340 10.10.1994 Ref. SCB 238 PCT.
  8. Babizhayev MA, Seguin M-C, Gueyene J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA “L-carnosine and carcinine act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities.” Biochem J. 304, 509-516.
  9. Babizhayev MA, “Antioxidant activity of L-carnosine, a natural histidine-containing di-peptide in crystalline lens.” Biochem. Biophys. Acta., 1989, 1004, 363-371.
  10. Babizhayev MA, Deyev Al “Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease.” Biochim. Biophys. Acta., 1989, 1004, 124-133.
  11. Babizhayev MA, Deyev Al “Free radical oxidation of lipid and thiol groups in genesis of cataract.” Biophysics (biofizika), 1986, 31, 119-125, Pergamon Journals Ltd.
  12. Kantha S, Wada S, Tanaka H, Takeushi M, Watabe S, Ochi H (1966), Biochem. Biophys. Res. Commun. 223, 278-292.
  13. Babizhayev MA, Deyev Al, Linberg LF “Lipid peroxidation as a possible cause of cataract.” Mech. Ageing Dev. 1988, 44, 69-89.
  14. Boldyrev AA, “Problems and perspectives in studying the biological role of carnosine” International Center for Biotechnology, Department of Biochemistry, Lomonosov, Moscow State University.
  15. Hipkiss A, (1998) Int. J. Biochem. Mol. Biol., 30, 863-868.
  16. Boldyrev AA, Dupin A, Bunin A, Babizhayev MA, Severin SE (1987), Biochem. Int., 15, 1107-1113.
  17. Wang AM, Ma C, Xie H, F Shen “Medical application of carnosine ” Department of Biochemistry and Neurobiology, Harbin Medical University, China.
  18. World Health Organisation, Ageing and Health, Website:


See Dr. Babizhayev Interview